TTD | Drug: D01TMQ

Drug General Information
Drug ID	D01TMQ
Former ID	DCL000733
Drug Name	Bupropion+naltrexone
Synonyms	Contrave (TN)
Drug Type	Small molecular drug
Indication	Obesity [ICD9: 278; ICD10:E66]		Phase 3	[532233]
Company	Orexigen Therapeutics
Formula	C13H18ClNO
PubChem Compound ID	444
Target and Pathway
Target(s)	Dopamine reuptake	Target Info	Inhibitor	[536710]
	Sodium-dependent noradrenaline transporter	Target Info	Inhibitor	[536710]
	Opioid receptor	Target Info	Antagonist	[536710]
PANTHER Pathway	Adrenaline and noradrenaline biosynthesis
Reactome	Na+/Cl- dependent neurotransmitter transporters
WikiPathways	Monoamine Transport
	NRF2 pathway
	Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
References
Ref 532233	A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013 May;21(5):935-43.
Ref 536710	Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.

Drug Information